{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:01:26Z","timestamp":1790949686719,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K11624"],"award-info":[{"award-number":["24K11624"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10067-025-07398-9","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:08:10Z","timestamp":1744214890000},"page":"2431-2438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical features and risk factors of flare in anti-synthetase syndrome"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3667-2721","authenticated-orcid":false,"given":"Anna","family":"Hasegawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-7556","authenticated-orcid":false,"given":"Kazuhiro","family":"Kurasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sakaue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoka","family":"Hiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Miyao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayae","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reika","family":"Maezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5169-7536","authenticated-orcid":false,"given":"Masafumi","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0574-9611","authenticated-orcid":false,"given":"Kei","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"issue":"4","key":"7398_CR1","doi-asserted-by":"publisher","first-page":"e60442","DOI":"10.1371\/journal.pone.0060442","volume":"8","author":"Y Hamaguchi","year":"2013","unstructured":"Hamaguchi Y, Fujimoto M, Matsushita T, Kaji K, Komura K, Hasegawa M et al (2013) Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One 8(4):e60442","journal-title":"PLoS One"},{"issue":"1","key":"7398_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","volume":"73","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP et al (2014) Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 73(1):227\u201332","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"7398_CR3","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3899\/jrheum.161480","volume":"44","author":"J Shi","year":"2017","unstructured":"Shi J, Li S, Yang H, Zhang Y, Peng Q, Lu X et al (2017) Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J Rheumatol 44(7):1051\u20137","journal-title":"J Rheumatol"},{"issue":"3","key":"7398_CR4","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s10067-022-06404-8","volume":"42","author":"R Wang","year":"2023","unstructured":"Wang R, Zhao Y, Qi F, Wu X, Wang Y, Xu Y et al (2023) Analysis of the clinical features of antisynthetase syndrome: a retrospective cohort study in China. Clin Rheumatol 42(3):703\u20139","journal-title":"Clin Rheumatol"},{"issue":"3","key":"7398_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/08916930600622884","volume":"39","author":"H Yoshifuji","year":"2006","unstructured":"Yoshifuji H, Fujii T, Kobayashi S, Imura Y, Fujita Y, Kawabata D et al (2006) Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 39(3):233\u201341","journal-title":"Autoimmunity"},{"issue":"5","key":"7398_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3899\/jrheum.180778","volume":"46","author":"H Hozumi","year":"2019","unstructured":"Hozumi H, Fujisawa T, Nakashima R, Yasui H, Suzuki Y, Kono M et al (2019) Efficacy of glucocorticoids and calcineurin inhibitors for anti-aminoacyl-tRNA synthetase antibody-positive polymyositis\/dermatomyositis-associated interstitial lung disease: a propensity score-matched analysis. J Rheumatol 46(5):509\u201317","journal-title":"J Rheumatol"},{"issue":"2","key":"7398_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.resinv.2019.10.004","volume":"58","author":"R Takei","year":"2020","unstructured":"Takei R, Yamano Y, Kataoka K, Yokoyama T, Matsuda T, Kimura T et al (2020) Predictive factors for the recurrence of anti-aminoacyl-tRNA synthetase antibody-associated interstitial lung disease. Respir Investig 58(2):83\u201390","journal-title":"Respir Investig"},{"issue":"8","key":"7398_CR8","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1007\/s10067-020-04979-8","volume":"39","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Ge Y, Yang H, Chen H, Tian X, Huang Z et al (2020) Clinical features and outcomes of the patients with anti-glycyl tRNA synthetase syndrome. Clin Rheumatol 39(8):2417\u201324","journal-title":"Clin Rheumatol"},{"issue":"3","key":"7398_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10067-022-06424-4","volume":"42","author":"H Chen","year":"2023","unstructured":"Chen H, Liu H, Lyu W, Liu Y, Huang M, Zhang Y et al (2023) An observational study of clinical recurrence in patients with interstitial lung disease related to the antisynthetase syndrome. Clin Rheumatol 42(3):711\u201320","journal-title":"Clin Rheumatol"},{"issue":"7","key":"7398_CR10","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1111\/crj.12797","volume":"12","author":"K Isoda","year":"2018","unstructured":"Isoda K, Kotani T, Takeuchi T, Konma J, Ishida T, Hata K et al (2018) Potential of Krebs von den Lungen-6 as a predictor of relapse in interstitial pneumonia with anti-aminoacyl tRNA synthetase antibodies-positive dermatomyositis. Clin Respir J 12(7):2235\u201341","journal-title":"Clin Respir J"},{"issue":"1","key":"7398_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1590\/S1806-37132011000100015","volume":"37","author":"J Solomon","year":"2011","unstructured":"Solomon J, Swigris JJ, Brown KK (2011) Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol 37(1):100\u20139","journal-title":"J Bras Pneumol"},{"issue":"12","key":"7398_CR12","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/art.40320","volume":"69","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, de Visser M et al (2017) 2017 European League against Rheumatism\/American College of Rheumatology Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol 69(12):2271\u201382","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"7398_CR13","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1590\/S0482-50042013000400007","volume":"53","author":"FH Souza","year":"2013","unstructured":"Souza FH, Cruellas MG, Levy-Neto M, Shinjo SK (2013) Anti-synthetase syndrome: anti-PL-7, anti-PL-12 and anti-EJ. Rev Bras Reumatol 53(4):352\u20137","journal-title":"Rev Bras Reumatol"},{"issue":"10","key":"7398_CR14","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","volume":"11","author":"I Marie","year":"2012","unstructured":"Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C et al (2012) Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 11(10):739\u201345","journal-title":"Autoimmun Rev"},{"key":"7398_CR15","doi-asserted-by":"crossref","unstructured":"Kouranloo K, Dey M, Elwell H, Yioe V, Spencer LG, Cotton CV. 2024 Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: a systematic literature review. Rheumatology (Oxford)","DOI":"10.1093\/rheumatology\/keae403"},{"issue":"8","key":"7398_CR16","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/rheumatology\/kep157","volume":"48","author":"M Sem","year":"2009","unstructured":"Sem M, Molberg O, Lund MB, Gran JT (2009) Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford) 48(8):968\u201371","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"7398_CR17","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","volume":"54","author":"H Andersson","year":"2015","unstructured":"Andersson H, Sem M, Lund MB, Aalokken TM, Gunther A, Walle-Hansen R et al (2015) Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford) 54(8):1420\u20138","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"7398_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","volume":"11","author":"TM Maher","year":"2023","unstructured":"Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP et al (2023) Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med 11(1):45\u201354","journal-title":"Lancet Respir Med"},{"key":"7398_CR19","doi-asserted-by":"publisher","first-page":"152474","DOI":"10.1016\/j.semarthrit.2024.152474","volume":"68","author":"X Shan","year":"2024","unstructured":"Shan X, Wu S, Chen X, Ge Y (2024) Janus kinase inhibition (JAKi) therapy in refractory anti-synthetase syndrome: a retrospective cohort study. Semin Arthritis Rheum 68:152474","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"7398_CR20","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.1007\/s00330-019-06152-5","volume":"29","author":"H Liu","year":"2019","unstructured":"Liu H, Xie S, Liang T, Ma L, Sun H, Dai H et al (2019) Prognostic factors of interstitial lung disease progression at sequential HRCT in anti-synthetase syndrome. Eur Radiol 29(10):5349\u201357","journal-title":"Eur Radiol"},{"issue":"8","key":"7398_CR21","first-page":"781","volume":"382","author":"KR Flaherty","year":"2020","unstructured":"Flaherty KR, Wells AU, Brown KK (2020) Nintedanib in progressive fibrosing interstitial lung diseases. Reply N Engl J Med 382(8):781","journal-title":"Reply N Engl J Med"},{"issue":"7","key":"7398_CR22","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1007\/s10067-023-06583-y","volume":"42","author":"H Fu","year":"2023","unstructured":"Fu H, Zheng Z, Zhang Z, Yang Y, Cui J, Wang Z et al (2023) Correction to: Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease. Clin Rheumatol 42(7):1997\u20138","journal-title":"Clin Rheumatol"},{"issue":"1","key":"7398_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/rheumatology\/keu166","volume":"54","author":"T Kurita","year":"2015","unstructured":"Kurita T, Yasuda S, Oba K, Odani T, Kono M, Otomo K et al (2015) The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (Oxford) 54(1):39\u201344","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"7398_CR24","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10067-017-3854-8","volume":"37","author":"M Nakazawa","year":"2018","unstructured":"Nakazawa M, Kaneko Y, Takeuchi T (2018) Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study. Clin Rheumatol 37(3):765\u201371","journal-title":"Clin Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07398-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07398-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07398-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T13:20:42Z","timestamp":1749129642000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07398-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["7398"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07398-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"16 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standard"}},{"value":"KK has received research grant from AbbVie Inc.. MA has received research grant from Eli Lilly Japan K.K.. KI has received research grant from Mitsubishi-Tanabe Pharma Corporation and speaker\u2019s fee from AbbVie Inc. and Eli Lilly Japan K.K.. The other authors have no competing interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}